Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Source: OncLive, February 2025
Mark Faries, MD, surgical oncologist, Cedars?Sinai, The Angeles Clinic and Research Institute; associate director, Surgical Oncology Experimental Therapeutics, Cedars Sinai Department of Surgery; and head, surgical oncology, Cedars-Sinai Medical Center, discusses how CAR T-cell therapies and transgenic T-cell receptor (TCR) cell therapies compare with current tumor-infiltrating lymphocyte (TIL) approaches in melanoma.
CAR T-cell and TCR therapies represent potential advancements over other adoptive cell therapies in melanoma, Faries begins. TIL therapy relies on naturally occurring lymphocytes that have infiltrated the tumor, recognizing melanoma cells through the body’s innate immune response, he explains. These cells are harvested, expanded ex vivo, and reinfused to enhance their antitumor activity, he says.
In contrast, CAR T-cell and transgenic TCR therapies involve genetic engineering to create tumor-specific immune cells, Faries states. Unlike TIL therapy, which requires tumor-infiltrating cells, these approaches utilize peripheral blood lymphocytes that are modified in the laboratory to specifically recognize melanoma-associated antigens, he details. CAR T-cell therapy employs chimeric antigen receptors to enable T cells to target surface antigens, whereas transgenic TCR therapy engineers T cells to recognize intracellular tumor antigens presented by major histocompatibility complex molecules, Faries explains.